In the fourth stratetgy, CIITA-ChIP probes derived from Raji were compared with CIITA-ChIP probes prepared from a cell line (SJO) derived from an RFX5-deficient BLS patient. The gene discussed is RFX5; the disease is MHC class II deficiency.